

Docket No. 6267.N
Serial No. 09/836,804

P.2

Amendments to the Claims


This listing of claims replaces all previous listings.

Claims 1 - 6 (cancelled)

(wherein said mammal is not suffering from a bacterial infection)

Se D
10/26/04

Claim 7. (Currently Amended) A method of treating osteoporosis or bone resorption in a vertebrate mammal in need thereof comprising the administering to the vertebrate mammal an effective amount of a compound of formula:

wherein Z₁ is -O₂S-, -O-, -N(R¹⁰⁷)-, -OS-, or -S-;

w is 0, 1, 2, or 3;

R²³ and R²⁴ are the same or different and can be H or F; andR¹ is H, NH₂, NHalkylC₁-C₄, N(alkylC₁-C₄)₂,alkylC₁-C₄; OalkylC₁-C₄; SalkylC₁-C₄; alkylC₁-C₄ substituted with 1-3F, 1-2Cl,CN, or -COOalkylC₁-C₄, or cycloalkylC₃-C₆, wherein in each occurrence of the alkyl group may be straight or branched; andR¹⁰⁷ is

- a) R¹⁰⁸O-C(R¹¹⁰)(R¹¹¹)-C(O)-,
- b) R¹⁰⁸O-C(O)-,
- c) R¹⁰⁸-C(O)-,
- d) R¹⁰⁸-SO₂-,
- e) NC-CH₂-,
- f) FCHCH₂-; or
- g) R¹³⁰R¹³¹NSO₂-;

wherein R¹⁰⁷ is H, CH₃-, phenyl-CH₂-, or CH₂C(O); each of R¹⁰⁸ and R¹¹¹ is selected from H or CH₃; R¹⁰⁹ is alkylC₁-C₃ or phenyl; R¹⁰⁸ is H, alkylC₁-C₄, aryl(CH₂)₀₋₅, CNCH₂-, ClCH₂-, Cl₂HC-, F₂HC-, or cycloalkylC₃-C₆; R¹³⁰ and R¹³¹ are the same or different and are selected from H, alkylC₁-C₄, or R¹³⁰ and R¹³¹ taken together with the nitrogen to which each is attached forms a monocyclic heterocyclic ring having from 3 to 6 carbon atoms.

Docket No. 6267.N
Serial No. 09/836,804
P.3

Claim 8. (Original) The method according to claim 7 wherein said mammal is a human.

Claim 9. (Original) The method according to claim 7 wherein the compound is administered in the range of about 0.1 to about 100 mg/kg of mammal body weight/day.

Claim 10. (Original) The method according to claim 7 wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.

Claim 11. (currently amended) The method according to claim 7 wherein said compound is selected from the group consisting of:

(S)-trans-[[3-[3-Fluoro-4-(tetrahydro-1-oxide-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea; and

(S)-trans-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide, thiomorpholine S-oxide; and

pharmaceutically acceptable salts thereof.

Claim 12. (Previously Presented) The method according to claim 7 wherein said mammal is not suffering from an bacterial infection.

Claim 13. (Cancelled)